ACAD · Acadia Pharmaceuticals Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · ACAD

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.07B	$957.80M	$726.44M	$517.24M	$484.14M	$441.75M
Cost of Revenue	$89.00M	$81.84M	$41.64M	$10.17M	$10.84M	$10.21M
Gross Profit	$982.51M	$875.96M	$684.80M	$507.07M	$473.30M	$431.54M
R&D	$328.80M	$303.25M	$351.62M	$361.57M	$239.41M	$319.13M
SG&A	$548.89M	$488.43M	$406.56M	$369.09M	$396.03M	$388.66M
Total Operating Expenses	$966.69M	$727.00M	$799.82M	$740.83M	$654.58M	$728.34M
D&A	$871.0K	$920.0K	$1.46M	$2.03M	$2.24M	$1.46M
Operating Income	$104.81M	$230.79M	($73.38M)	($223.60M)	($170.44M)	($286.59M)
Interest Expense	-	-	-	-	-	-
Income Tax	($252.10M)	$31.62M	$10.25M	$2.53M	$351.0K	$611.0K
Net Income	$391.00M	$226.45M	($61.29M)	($215.97M)	($167.87M)	($281.58M)
EPS - Basic	$2.32	$1.37	($0.37)	($1.79)	($1.05)◇	-
EPS - Diluted	$2.30	$1.36	($0.37)	($1.79)	($1.05)◇	-

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$177.69M	$319.59M	$188.66M	$114.85M	$147.44M	$326.03M
Accounts Receivable	$121.46M	$98.74M	$98.27M	$62.20M	$64.37M	$48.25M
Inventory	$111.37M	$91.69M	$40.45M	$11.56M	$14.10M	$9.68M
Accounts Payable	$10.90M	$16.19M	$17.54M	$12.75M	$6.88M	$8.49M
Current Assets	$1.06B	$938.32M	$616.13M	$507.94M	$617.82M	$717.62M
Total Assets	$1.56B	$1.19B	$748.96M	$587.81M	$700.12M	$782.62M
Current Liabilities	$277.11M	$394.87M	$254.25M	$125.63M	$96.07M	$105.97M
Long-term Debt	-	-	-	-	-	-
Total Liabilities	$336.81M	$454.96M	$317.20M	$187.40M	$159.23M	$155.61M
Stockholders' Equity	$1.23B	$732.79M	$431.75M	$400.41M	$540.89M	$627.01M
Retained Earnings	($1.81B)	($2.20B)	($2.43B)	($2.37B)	($2.15B)	($1.99B)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$109.84M	$157.72M	$16.70M	($114.03M)	($125.66M)	($136.17M)
Investing Cash Flow	($302.56M)	($30.54M)	$32.00M	$73.24M	($71.10M)	$192.51M
Financing Cash Flow	$49.88M	$6.84M	$25.13M	$8.20M	$18.16M	$81.00M
CapEx	$4.69M	$523.0K	$50.0K	$0	$1.12M	$7.59M
Free Cash Flow	$105.15M	$157.20M	$16.65M	($114.03M)	($126.78M)	($143.75M)

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	91.7%	91.5%	94.3%	98.0%	97.8%	97.7%
Operating margin	9.8%	24.1%	-10.1%	-43.2%	-35.2%	-64.9%
EBITDA margin	9.9%	24.2%	-9.9%	-42.8%	-34.7%	-64.5%
Net margin	36.5%	23.6%	-8.4%	-41.8%	-34.7%	-63.7%
Free cash flow margin	9.8%	16.4%	2.3%	-22.0%	-26.2%	-32.5%
FCF / Net income	0.27	0.69	-0.27	0.53	0.76	0.51
R&D / Revenue	30.7%	31.7%	48.4%	69.9%	49.5%	72.2%
SG&A / Revenue	51.2%	51.0%	56.0%	71.4%	81.8%	88.0%
Effective tax rate	-181.5%	12.3%	-	-	-	-
Return on assets	25.0%	19.1%	-8.2%	-36.7%	-24.0%	-36.0%
Return on equity	31.9%	30.9%	-14.2%	-53.9%	-31.0%	-44.9%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	3.83	2.38	2.42	4.04	6.43	6.77
Quick ratio	3.43	2.14	2.26	3.95	6.28	6.68
Cash ratio	0.64	0.81	0.74	0.91	1.53	3.08
Leverage
Debt / Equity	-	-	-	-	-	-
Debt / Assets	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-	-	-	-	-	-
Equity multiplier	1.27	1.62	1.73	1.47	1.29	1.25
Liabilities / Assets	0.22	0.38	0.42	0.32	0.23	0.20
Efficiency
Asset turnover	0.69	0.81	0.97	0.88	0.69	0.56
Inventory turnover	0.80	0.89	1.03	0.88	0.77	1.05
Days sales outstanding	41d	38d	49d	44d	49d	40d
Days inventory outstanding	457d	409d	355d	415d	475d	346d
Days payable outstanding	45d	72d	154d	458d	231d	304d
Cash conversion cycle	453d	374d	250d	1d	292d	82d
Valuation
P / E	11.6x	13.5x	-	-	-	-
P / B	3.7x	4.2x	0.0x	0.0x	0.0x	-
P / S	4.2x	3.2x	0.0x	0.0x	0.0x	-
EV / EBITDA	41.3x	11.8x	-	-	-	-
Growth
Revenue growth (YoY)	11.9%	31.8%	40.4%	6.8%	9.6%	30.3%
Revenue CAGR (3y)	27.5%	25.5%	18.0%	15.1%	29.3%	52.4%
Revenue CAGR (5y)	19.4%	23.1%	26.6%	32.9%	94.6%	491.5%
Gross profit growth (YoY)	12.2%	27.9%	35.1%	7.1%	9.7%	31.7%
Operating income growth (YoY)	-54.6%	-	67.2%	-31.2%	40.5%	-16.2%
Net income growth (YoY)	72.7%	-	71.6%	-28.7%	40.4%	-19.7%
EPS growth (YoY)	69.1%	-	79.3%	-70.5%	-	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	-33.1%	844.0%	-	10.1%	11.8%	5.6%
FCF CAGR (5y)	-	-	-	-	-	-
Book value growth (YoY)	67.5%	69.7%	7.8%	-26.0%	-13.7%	-10.3%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$1.07B total

Reportable Segment Aggregation Before Other Operating Segment$1.07B · 100.0%

Product / service

$1.07B total

Nuplazid$680.09M · 63.5%

Daybue$391.42M · 36.5%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

1.80

Grey zone

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

5/9

Neutral

✓Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✗Cash flow > net income
-Long-term debt decreased
✓Current ratio improved
✗No share dilution
✓Gross margin improved
✗Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

Company	Revenue (last FY)	Net margin	ROE
LLY	$65.18B	31.7%	77.8%
UTHR	$3.18B	41.9%	18.8%
PFE	$62.58B	12.4%	9.0%
ZTS	$9.47B	28.2%	80.2%
VRTX	$12.00B	32.9%	21.2%

Comparing ACADIA PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.